John Overdeck’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-48,861
| Closed | -$11.2K | – | 3578 |
|
|
2024
Q4 | $11.2K | Buy |
48,861
+20,386
| +72% | +$24.5K | ﹤0.01% | 3129 |
|
|
2024
Q3 | $61.2K | Sell |
28,475
-11,791
| -29% | -$42.4K | ﹤0.01% | 2956 |
|
|
2024
Q2 | $208K | Sell |
40,266
-28,017
| -41% | -$147K | ﹤0.01% | 2723 |
|
|
2024
Q1 | $365K | Buy |
68,283
+13,629
| +25% | +$94.2K | ﹤0.01% | 2472 |
|
|
2023
Q4 | $426K | Buy |
+54,654
| New | +$187K | ﹤0.01% | 2542 |
|
|
2023
Q3 | – | Sell |
-19,584
| Closed | -$61.7K | – | 3276 |
|
|
2023
Q2 | $61.7K | Buy |
19,584
+5,984
| +44% | +$19.2K | ﹤0.01% | 2804 |
|
|
2023
Q1 | $36.3K | Buy |
13,600
+3,139
| +30% | +$12.2K | ﹤0.01% | 2791 |
|
|
2022
Q4 | $37.6K | Buy |
+10,461
| New | +$45.4K | ﹤0.01% | 2622 |
|
|
2022
Q2 | – | Sell |
-18,637
| Closed | -$222K | – | 3025 |
|
|
2022
Q1 | $222K | Buy |
18,637
+13,770
| +283% | +$246K | ﹤0.01% | 2311 |
|
|
2021
Q4 | $159K | Sell |
4,867
-4,261
| -47% | -$173K | ﹤0.01% | 3978 |
|
|
2021
Q3 | $408K | Sell |
9,128
-2,907
| -24% | -$142K | ﹤0.01% | 3431 |
|
|
2021
Q2 | $656K | Sell |
12,035
-9,003
| -43% | -$533K | ﹤0.01% | 2864 |
|
|
2021
Q1 | $1.57M | Buy |
21,038
+7,135
| +51% | +$741K | ﹤0.01% | 1894 |
|
|
2020
Q4 | $1.51M | Sell |
13,903
-1,448
| -9% | -$132K | ﹤0.01% | 1692 |
|
|
2020
Q3 | $1.36M | Sell |
15,351
-9,349
| -38% | -$1.06M | ﹤0.01% | 1559 |
|
|
2020
Q2 | $2.63M | Buy |
+24,700
| New | +$2.22M | 0.01% | 964 |
|
|
2020
Q1 | – | Sell |
-2,170
| Closed | -$150K | – | 3944 |
|
|
2019
Q4 | $150K | Buy |
+2,170
| New | +$132K | ﹤0.01% | 3477 |
|
|
2019
Q2 | – | Sell |
-1,854
| Closed | -$169K | – | 3738 |
|
|
2019
Q1 | $169K | Sell |
1,854
-2,922
| -61% | -$204K | ﹤0.01% | 2845 |
|
|
2018
Q4 | $266K | Sell |
4,776
-932
| -16% | -$70.8K | ﹤0.01% | 2541 |
|
|
2018
Q3 | $680K | Sell |
5,708
-6,004
| -51% | -$696K | ﹤0.01% | 2255 |
|
|
2018
Q2 | $1.2M | Buy |
+11,712
| New | +$1.45M | ﹤0.01% | 2017 |
|
|
2018
Q1 | – | Sell |
-2,120
| Closed | -$206K | – | 3592 |
|
|
2017
Q4 | $206K | Buy |
2,120
+944
| +80% | +$127K | ﹤0.01% | 2915 |
|
|
2017
Q3 | $173K | Buy |
+1,176
| New | +$221K | ﹤0.01% | 2611 |
|
Other funds holding SYRS
BBA
1CM
XT
John Overdeck's SYRS Position: Q1 2025 in Review
John Overdeck sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 48,861 shares — an estimated $11.2K sold.
John Overdeck first reported a position in SYRS in Q3 2017 and held it in 23 quarters. The position peaked at $2.63M in Q2 2020. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.
- John Overdeck reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- John Overdeck sold 48,861 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $11.2K.
- John Overdeck first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 23 quarters.
- John Overdeck's Syros Pharmaceuticals, Inc. Common Stock position peaked at $2.63M in Q2 2020.
- 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.
Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.